Title:
DIAGNOSTIC USE OF HIGHLY TOXIC AMYLOID OLIGOMER
Document Type and Number:
WIPO Patent Application WO/2024/032823
Kind Code:
A1
Abstract:
A use of a new highly toxic amyloid oligomer Aβo*3F as a target for diagnosing Alzheimer's disease (AD) in the early stage and the middle-late stage and mild cognitive impairment (MCI) caused by AD. The Aβo*3F specifically binds to a 3F antibody and is present in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and patients with MCI caused by AD, and the levels show highly significant differences in CSF, blood and/or brain tissue of AD patients, MCI patients and healthy elderly persons. In addition, the Aβo*3F is an ultra-highly toxic oligomer, is the most important toxic component in an Aβ oligomer mixture, has a strong pathogenic effect, and plays a key role in the occurrence and development of AD.
Inventors:
LIU RUITIAN (CN)
HUANG YARU (CN)
XIE XIXIU (CN)
YU XIAOLIN (CN)
JI SHAOYANG (CN)
HUANG YARU (CN)
XIE XIXIU (CN)
YU XIAOLIN (CN)
JI SHAOYANG (CN)
Application Number:
PCT/CN2023/121351
Publication Date:
February 15, 2024
Filing Date:
September 26, 2023
Export Citation:
Assignee:
SHEN ZHEN WISDOM BIOPHARM CO LTD (CN)
International Classes:
G01N33/68
Foreign References:
| CN111518206A | 2020-08-11 | |||
| CN101827862A | 2010-09-08 | |||
| CN102597233A | 2012-07-18 | |||
| CN103782171A | 2014-05-07 | |||
| CN110325547A | 2019-10-11 | |||
| CN113508300A | 2021-10-15 | |||
| US20050124016A1 | 2005-06-09 | |||
| US20130295095A1 | 2013-11-07 | |||
| US20190376984A1 | 2019-12-12 |
Attorney, Agent or Firm:
BEIJING INTELLEGAL INTELLECTUAL PROPERTY AGENT LTD. (CN)
Download PDF: